Last reviewed · How we verify
Olaparib tablets
Olaparib (Lynparza) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor developed by AstraZeneca for DNA damage repair-deficient cancers, particularly those with BRCA mutations. The drug has achieved multiple FDA approvals across ovarian, breast, pancreatic, and prostate cancers in both treatment and maintenance settings, establishing it as a cornerstone therapy in precision oncology. Currently in Phase 2 development with 18 active trials, olaparib is being evaluated in combination regimens (e.g., with pembrolizumab, abiraterone) and expanded indications including triple-negative breast cancer, non-small-cell lung cancer, and castration-resistant prostate cancer. The drug generated peak annual revenues exceeding $1.5B globally, with strong market penetration in BRCA-mutated populations and expanding use in homologous recombination deficiency (HRD) biomarker-selected cohorts. Competitive differentiation stems from its oral bioavailability, established safety profile, and extensive clinical validation across multiple tumor types, though it faces competition from other PARP inhibitors (rucaparib, niraparib, talazoparib) and emerging DNA damage response inhibitors. AstraZeneca continues to expand olaparib's clinical footprint through combination studies and geographic expansion, particularly in Asia-Pacific markets.
At a glance
| Generic name | Olaparib tablets |
|---|---|
| Also known as | Lynparza |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olaparib tablets CI brief — competitive landscape report
- Olaparib tablets updates RSS · CI watch RSS
- AstraZeneca portfolio CI